CHICAGO - Pharma deals have become the last port in a storm as venture capital, initial public offerings (IPO) and funding from other sources have dried up. But while more relationships are being consummated, pharma is pushing the risk back onto biotech partners, with smaller up-front payments and many milestones staged along the long route to approval. (BioWorld International)

LONDON - Oxford Immunotec Ltd. raised $26 million in a fourth-round funding, which it said will enable it to increase sales of its T-cell diagnostic for tuberculosis and take the company through to profitability. (BioWorld International)